الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic presentation of metabolic syndrome that affect liver and adversely affects many extrahepatic organ systems, including the cardiovascular system. NAFLD independently increases the risk of CVD specially left ventricular dysfunction. This risk parallels the severity of NAFLD (especially the stage of liver fibrosis) The perception of nonalcoholic fatty liver disease as an uncommon and benign condition is rapidly changing as the disease follows a more aggressive course with necro-inflammation and fibrosis (i.e.nonalcoholic steatohepatitis…NASH). NASH is a leading cause of end-stage liver disease and contributes to cardiovascular disease. Early detection of NAFLD helps in early management and prevents its progression into steatohepatitis and liver cirrhosis. The most common cardiac anomaly in NAFD is left ventricular hypertrophy (LVH), which has been observed in the majority of patients and directly correlated with the degree of NAFLD. LVH is an ominous prognostic sign that may result in systolic and/or diastolic dysfunction and is an independent risk factor for arrhythmias, sudden death, heart failure and myocardial ischaemia. Whole blood viscosity (WBV) is a more sensitive predictor of CVD events. Therefore, the aim of this study was to evaluate whole blood viscosity as a predictor of left ventricular hypertrophy in NAFLD Patients.